INS and type 1 diabetes mellitus: Rapini et al. [27] conducted a two-centre prospective study enrolling 19 patients with T1DM between 2 and 7 years of age who were switched to AHCL from multiple daily injections or open-loop insulin therapy; after 6 months of follow-up, there was a significant reduction in median HbA1c (56.3 vs. 55 mmol/mol) and a reduction in mild hyperglycaemia (TAR 180–250 mg/dL, 25% vs. 21%) and in severe hyperglycaemia (TAR > 250 mg/dL, 11% vs. 7%), with a small increase in mild hypoglycaemia (TBR 54–70 mg/dL, 2% vs. 2.5%).